Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Mnov crawled time : 00:00 save search
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
Published: 2023-11-19 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 11.8%
H: 8.54%
C: 3.52%
mn-166 meeting trial results glioblastoma
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
Published: 2023-05-14 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 1.85%
H: 2.27%
C: 0.23%
mn-166 europe patent infection grant
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
Published: 2023-04-30 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 1.42%
H: 2.8%
C: -2.34%
mn-001 patent treatment canada nash
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
Published: 2023-03-09 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 0.0%
H: 4.15%
C: 3.23%
mn-166 lung extension medical contract
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
Published: 2023-02-20 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 0.86%
H: 2.13%
C: -2.13%
mn-166 tumor therapeutics glioblastoma
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
Published: 2023-02-08 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 3.39%
H: 2.01%
C: 0.41%
mn-166 covid canada health grants trial authorization
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
Published: 2023-01-30 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: -0.42%
alcohol trial phase 2b
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
Published: 2023-01-12 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.8%
mn-166 treatment trial glioblastoma
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)
Published: 2023-01-05 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 3.56%
H: 2.58%
C: 2.58%
mn-166 fda
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
Published: 2022-12-06 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 5.02%
H: 0.8%
C: -3.98%
mn-001 meeting diabetes positive results international
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
Published: 2022-12-05 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 0.4%
H: 2.42%
C: -3.63%
mn-166 alcohol drug trial positive results
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
Published: 2022-09-15 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 1.36%
H: 2.69%
C: 2.69%
conference
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
Published: 2022-09-14 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: -0.46%
H: 4.65%
C: 2.33%
mn-166 treatment patent glioblastoma
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
Published: 2022-09-13 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 2.82%
H: 2.74%
C: -1.37%
mn-001 treatment patent canada hypercholesterolemia
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
Published: 2022-08-09 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 2.13%
H: 1.67%
C: -2.08%
mn-001 meeting presentation diabetes international
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
Published: 2022-07-21 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 0.41%
H: 1.22%
C: -0.41%
mn-166
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
Published: 2022-06-29 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.78%
mn-166 extension contract
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
Published: 2022-06-22 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 1.59%
H: 1.18%
C: -1.57%
mn-001 research japan collaboration
MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference
Published: 2022-04-21 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: -5.13%
H: 2.36%
C: -1.01%
conference
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research
Published: 2022-04-20 (Crawled : 00:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
mn-166 research molecular cancer publication
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.